vs
DYNEX CAPITAL INC（DX）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是DYNEX CAPITAL INC的1.5倍（$65.1M vs $43.5M），DYNEX CAPITAL INC同比增速更快（531.3% vs 3.6%），过去两年DYNEX CAPITAL INC的营收复合增速更高（75.8% vs 5.1%）
Dynex Capital Inc是一家总部位于美国的上市房地产投资信托公司，专注于投资和管理抵押贷款支持证券、住宅及商业抵押贷款等各类抵押相关资产组合，通过稳健运营为股东创造稳定分红和长期资本增值。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
DX vs MLAB — 直观对比
营收规模更大
MLAB
是对方的1.5倍
$43.5M
营收增速更快
DX
高出527.7%
3.6%
两年增速更快
DX
近两年复合增速
5.1%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $43.5M | $65.1M |
| 净利润 | — | $3.6M |
| 毛利率 | — | 64.2% |
| 营业利润率 | — | 12.2% |
| 净利率 | — | 5.6% |
| 营收同比 | 531.3% | 3.6% |
| 净利润同比 | — | 316.6% |
| 每股收益（稀释后） | $1.59 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DXMLAB
| Q4 25 | $43.5M | $65.1M | ||
| Q3 25 | $30.6M | $60.7M | ||
| Q2 25 | $23.1M | $59.5M | ||
| Q1 25 | $17.1M | $62.1M | ||
| Q4 24 | — | $62.8M | ||
| Q3 24 | — | $57.8M | ||
| Q2 24 | — | $58.2M | ||
| Q1 24 | $-3.2M | $58.9M |
净利润DXMLAB
| Q4 25 | — | $3.6M | ||
| Q3 25 | $150.4M | $2.5M | ||
| Q2 25 | $-13.6M | $4.7M | ||
| Q1 25 | $-3.1M | $-7.1M | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | — | $3.4M | ||
| Q2 24 | — | $3.4M | ||
| Q1 24 | $40.1M | $-254.6M |
毛利率DXMLAB
| Q4 25 | — | 64.2% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 62.0% | ||
| Q1 25 | — | 61.8% | ||
| Q4 24 | — | 63.3% | ||
| Q3 24 | — | 61.3% | ||
| Q2 24 | — | 64.0% | ||
| Q1 24 | — | 62.1% |
营业利润率DXMLAB
| Q4 25 | — | 12.2% | ||
| Q3 25 | — | 7.8% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 9.2% | ||
| Q3 24 | — | 6.1% | ||
| Q2 24 | — | 9.6% | ||
| Q1 24 | — | -460.6% |
净利率DXMLAB
| Q4 25 | — | 5.6% | ||
| Q3 25 | 491.3% | 4.1% | ||
| Q2 25 | -58.8% | 8.0% | ||
| Q1 25 | -18.0% | -11.4% | ||
| Q4 24 | — | -2.7% | ||
| Q3 24 | — | 5.9% | ||
| Q2 24 | — | 5.8% | ||
| Q1 24 | -1256.8% | -432.2% |
每股收益（稀释后）DXMLAB
| Q4 25 | $1.59 | $0.65 | ||
| Q3 25 | $1.08 | $0.45 | ||
| Q2 25 | $-0.14 | $0.85 | ||
| Q1 25 | $-0.06 | $-1.30 | ||
| Q4 24 | — | $-0.31 | ||
| Q3 24 | — | $0.63 | ||
| Q2 24 | — | $0.62 | ||
| Q1 24 | $0.64 | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $531.0M | $29.0M |
| 总债务越低越好 | — | $68.4M |
| 股东权益账面价值 | $2.5B | $186.7M |
| 总资产 | $17.3B | $434.8M |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资DXMLAB
| Q4 25 | $531.0M | $29.0M | ||
| Q3 25 | $491.0M | $20.4M | ||
| Q2 25 | $387.5M | $21.3M | ||
| Q1 25 | $327.4M | $27.3M | ||
| Q4 24 | — | $27.3M | ||
| Q3 24 | — | $24.3M | ||
| Q2 24 | — | $28.5M | ||
| Q1 24 | $295.7M | $28.2M |
总债务DXMLAB
| Q4 25 | — | $68.4M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | — | $70.3M | ||
| Q1 25 | — | $71.3M | ||
| Q4 24 | — | $72.2M | ||
| Q3 24 | — | $73.1M | ||
| Q2 24 | — | $74.1M | ||
| Q1 24 | — | — |
股东权益DXMLAB
| Q4 25 | $2.5B | $186.7M | ||
| Q3 25 | $2.0B | $178.5M | ||
| Q2 25 | $1.6B | $172.5M | ||
| Q1 25 | $1.4B | $159.8M | ||
| Q4 24 | — | $155.2M | ||
| Q3 24 | — | $161.5M | ||
| Q2 24 | — | $150.7M | ||
| Q1 24 | $958.5M | $145.4M |
总资产DXMLAB
| Q4 25 | $17.3B | $434.8M | ||
| Q3 25 | $14.2B | $430.4M | ||
| Q2 25 | $11.3B | $435.7M | ||
| Q1 25 | $9.0B | $433.3M | ||
| Q4 24 | — | $433.3M | ||
| Q3 24 | — | $454.1M | ||
| Q2 24 | — | $440.4M | ||
| Q1 24 | $6.3B | $446.8M |
负债/权益比DXMLAB
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $120.8M | $18.8M |
| 自由现金流经营现金流 - 资本支出 | — | $18.0M |
| 自由现金流率自由现金流/营收 | — | 27.7% |
| 资本支出强度资本支出/营收 | — | 1.1% |
| 现金转化率经营现金流/净利润 | — | 5.17× |
| 过去12个月自由现金流最近4个季度 | — | $37.9M |
8季度趋势，按日历期对齐
经营现金流DXMLAB
| Q4 25 | $120.8M | $18.8M | ||
| Q3 25 | $68.3M | $8.2M | ||
| Q2 25 | $31.9M | $1.9M | ||
| Q1 25 | $6.4M | $12.7M | ||
| Q4 24 | — | $18.1M | ||
| Q3 24 | — | $5.3M | ||
| Q2 24 | — | $10.7M | ||
| Q1 24 | $-17.1M | $12.9M |
自由现金流DXMLAB
| Q4 25 | — | $18.0M | ||
| Q3 25 | — | $7.1M | ||
| Q2 25 | — | $884.0K | ||
| Q1 25 | — | $11.9M | ||
| Q4 24 | — | $17.3M | ||
| Q3 24 | — | $3.5M | ||
| Q2 24 | — | $9.9M | ||
| Q1 24 | — | $12.3M |
自由现金流率DXMLAB
| Q4 25 | — | 27.7% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 19.2% | ||
| Q4 24 | — | 27.6% | ||
| Q3 24 | — | 6.0% | ||
| Q2 24 | — | 16.9% | ||
| Q1 24 | — | 21.0% |
资本支出强度DXMLAB
| Q4 25 | — | 1.1% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 1.3% | ||
| Q3 24 | — | 3.1% | ||
| Q2 24 | — | 1.5% | ||
| Q1 24 | — | 0.9% |
现金转化率DXMLAB
| Q4 25 | — | 5.17× | ||
| Q3 25 | 0.45× | 3.32× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.54× | ||
| Q2 24 | — | 3.17× | ||
| Q1 24 | -0.43× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DX
暂无分部数据
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
